Why is Alembic Pharma falling/rising?

As of 07-Jul, Alembic Pharmaceuticals Ltd. is currently priced at 1,000.00, reflecting a slight increase of 0.6 (0.06%). The stock's performance today is in line with its sector, although it has shown a decline of 4.09% over the past week. It is trading above its 20-day, 50-day, 100-day, and 200-day moving averages, but below its 5-day moving average. Notably, there has been a significant drop in investor participation, with delivery volume falling by 89.49% against the 5-day average. Despite a strong ability to service debt indicated by a low Debt to EBITDA ratio of 0.67 times and attractive valuation metrics, the stock has faced challenges, including a 7% decline in profits over the past year and a long-term growth rate of -7.30% in operating profit over the last five years.
In the broader market context, Alembic Pharmaceuticals has underperformed compared to the benchmark Sensex, which has gained 1.53% over the past month while the stock has only increased by 1.57%. The stock's year-to-date performance shows a decline of 5.58%, contrasting with the Sensex's gain of 6.79%. High institutional holdings at 20.37% suggest that knowledgeable investors are involved, but the stock's recent negative results, including a significant drop in profit after tax and a high debt-equity ratio, may contribute to a cautious outlook among investors. Overall, while there are some positive factors, the stock's recent movement reflects ongoing concerns about its long-term growth potential and profitability.